Riskpilot← Back to searchSign inGet full accessLABEX ApS
APSActiveCVR 19947394Gammel Køge Landevej 55, 5.Wholesale of pharmaceutical and medical goods · NACE 4646Est. 19961 employees
Revenue 2025
DKK 878K
-40% vs 2024
EBITDA margin
6.1%
-88% vs 2024
Equity ratio
18.3%
Financial strength
Net profit 2025
DKK 5K
-70% vs 2024
| Revenue | DKK 878K | -40% |
| EBITDA | DKK 54K | -88% |
| Net profit | DKK 5K | -70% |
| Total assets | DKK 4,3M | +70% |
| Equity | DKK 797K | +1% |
| Employees | 1 | — |
Legal name
LABEX ApS
CVR number
19947394
Legal form
Anpartsselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
18. december 1996
Share capital
DKK 200.000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-04-30
Financial year
January – December
Signatory rights
Selskabet forpligtes ved aftaler, som indgås på selskabets vegne af én direktør eller af 2 bestyrelsesmedlemmer i forening.
Company purpose
Selskabets formål er at drive handel.
Address
Gammel Køge Landevej 55, 5.
Phone
+4545661300
Email
regnskab@labex.dk
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 2.074 | 2.357 | 2.459 | 1.456 | 878 |
| Staff expenses | -1.229 | -1.933 | -1.974 | -1.015 | -824 |
| EBITDA | 845 | 424 | 485 | 441 | 54 |
| Depreciation & amort. | -506 | -509 | -509 | -447 | -10 |
| EBIT | 339 | -85 | -24 | -6 | 44 |
| Net financials | -151 | -70 | 98 | 23 | -39 |
| Profit before tax | 188 | -155 | 74 | 18 | 5 |
| Tax | -0 | -0 | -0 | -0 | -0 |
| Net profit | 188 | -155 | 74 | 18 | 5 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 6.119 | 3.974 | 4.473 | 2.551 | 4.345 |
| Equity | 855 | 700 | 774 | 792 | 797 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 5.264 | 3.273 | 3.698 | 1.759 | 3.548 |
| Total debt | 5.264 | 3.273 | 3.698 | 1.759 | 3.548 |
EBITDA margin
6.1%
This company
15.8%
Market median
-61% vs market
20212025
Equity ratio
18.3%
This company
38.2%
Market median
-52% vs market
20212025
Return on equity
0.7%
This company
18.4%
Market median
-96% vs market
20212025
Net profit margin
0.6%
This company
8.1%
Market median
-93% vs market
20212025
Asset turnover
0.20×
This company
1.12×
Market median
-82% vs market
20212025
Debt / equity
4.45×
This company
0.62×
Market median
-618% vs market
20212025
- Annual report 2025Filed via CVR / Virk · Period 2024-05-01 – 2025-04-30
- Annual report 2024Filed via CVR / Virk · Period 2023-05-01 – 2024-04-30
- Annual report 2023Filed via CVR / Virk · Period 2022-05-01 – 2023-04-30
- Annual report 2022Filed via CVR / Virk · Period 2021-05-01 – 2022-04-30
- Annual report 2021Filed via CVR / Virk · Period 2020-05-01 – 2021-04-30
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
MP Management | Management | 2022 |
| Former (1) | ||
GR Chief Executive Officer | Chief Executive Officer | 2013 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2020 | |
| Board of Directors | 2025 | |
| Chairman | 2017 | |
| Former (2) | ||
| Board of Directors | 2013 – 2017 | |
| Chairman | 2013 – 2017 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100% | 100% | 2002 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of LABEX ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Max Pihlqvist | Management | 0 companies |
| Gustav Richard Lundin | Chief Executive Officer | 0 companies |
| Bjarne Jensen | Board of Directors | 0 companies |
| Johan Erlandsson | Board of Directors | 0 companies |
| Gert Stefan karlsson | Board of Directors | 0 companies |
| Leif Gøran Pihlqvist | Chairman | 0 companies |
| Max Pihlqvist | Chairman | 0 companies |